CORAL GABLES, Fla., April 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025), taking place from April 26-29th in Las Vegas.
Mon, 28 Apr 2025 13:30:00 GMT Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase ...
Sun, 27 Apr 2025 06:13:00 GMT Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase ...
Sun, 27 Apr 2025 06:10:00 GMT Relmada Therapeutics, Inc. announced the presentation ... that planned studies may not demonstrate expected results. The press release emphasizes the high recurrence rate of NMIBC, which could ...
Sun, 27 Apr 2025 06:01:00 GMT About Relmada Therapeutics, Inc. Relmada Therapeutics ... forward-looking statements made by us or on our behalf. This press release contains statements which constitute “forward-looking ...
Thu, 24 Apr 2025 06:48:00 GMT About Relmada Therapeutics, Inc. Relmada Therapeutics ... forward-looking statements made by us or on our behalf. This press release contains statements which constitute “forward-looking ...
